产品展示
PAPP A Human/ 重组人妊娠联系质粒蛋白1
点击次数：308发布时间：2012/11/17 15:04:48
更新日期：2024/10/16 16:00:55
所 在 地：欧洲
产品型号：
优质供应
详细内容
慧嘉生物您实验身边的好伙伴
为客户提供“品质的产品”和“*优质的服务”
AssayBiotech CUSABIO Immunoway Santa Abcam Cst jackson Pierce Sigma Amresco Qiagen Cayman abnova millipore invitrogen merk ebioscience prospec lifespan BD
欢迎广大客户咨询，另有大量宣传海报和小礼品赠送。
网站：www.biohj.com
Q Q：
PAPP A Human/ 重组人妊娠联系质粒蛋白1
产品编号：ENZ-441
产品规格：2μg/10μg/1mg
Synonyms Pappalysin-1, Pregnancy-associated plasma protein A, PAPP-A, Insulin-like growth factor-dependent IGF-binding protein 4 protease, IGF-dependent IGFBP-4 protease, IGFBP-4ase, PAPPA, PAPA, DIPLA1, PAPPA1, ASBABP2. Introduction PAPPA is a large zinc binding protein, which acts as a metalloprotease ａnd specifically cleaves IGFBP-4 ａnd IGFBP-5, resulting in release of bound IGF. PAPP-A can also act as a regulator of IGF bioactivity in a number of biological systems, including the human ovary ａnd cardiovascular systems. It was shown that PAPP A levels are elevated in patients with unstable angina or acute myocardial infarction. Furthermore, PAPPA is believed to be involved in local proliferative processes such as wound healing ａnd bone remodeling. Moreover, PAPP-A is produced in high concentrations during pregnancy ａnd is released into the maternal circulation. In placenta, PAPP A is expressed in X cells in septa ａnd anchoring villi, ａnd in syncytiotrophoblasts in the chorionic villi.
Lower levels of PAPPA are found in an array of other tissues including kidney, myometrium, endometrium, ovaries, breast, prostate, bone marrow, colon, fibroblasts ａnd osteoblasts. PAPP-A is present in serum ａnd placenta during pregnancy; with levels increasing throughout pregnancy. Low levels of PAPP A are associated with a number of foetal chromosomal abnormalities, as well as pre-eclampsia ａnd stillbirth.
PAPPA levels may be a potentially highly specific marker for heart disease.
PAPP-A proteolytic activity is inhibited by targeting substrate exosite binding. Description PAPP-A Human Recombinant produced in E.Coli is single, a non-glycosylated, Polypeptide chain containing 191 amino acids fragment （81-271） corresponding to the PAPP-A "Jelly-Roll" domain fragment, having a total molecular mass of 30kDa ａnd fused with a 4.5kDa amino-terminal hexahistidine tag.
The PAPP-A is purified by proprietary chromatographic techniques. Source Escherichia Coli. Physical Appearance Sterile Filtered clear solution. Formulation PAPP-A protein is supplied in 1x PBS ａnd 50% glycerol. Stability Store at 4°C if entire vial will be used within 2-4 weeks.
Store, frozen at -20°C for longer periods of time.
Please avoid freeze thaw cycles. Purity Greater than 95.0% as determined by SDS-PAGE. Usage Prospec＇s products are furnished for LABORATORY RESEARCH USE ONLY. The product may not be used as drugs, agricultural or pesticidal products, food additives or household chemicals.
PAPP A Human/ 重组人妊娠联系质粒蛋白1
产品编号：ENZ-441
产品规格：2μg/10μg/1mg
Synonyms Pappalysin-1, Pregnancy-associated plasma protein A, PAPP-A, Insulin-like growth factor-dependent IGF-binding protein 4 protease, IGF-dependent IGFBP-4 protease, IGFBP-4ase, PAPPA, PAPA, DIPLA1, PAPPA1, ASBABP2. Introduction PAPPA is a large zinc binding protein, which acts as a metalloprotease ａnd specifically cleaves IGFBP-4 ａnd IGFBP-5, resulting in release of bound IGF. PAPP-A can also act as a regulator of IGF bioactivity in a number of biological systems, including the human ovary ａnd cardiovascular systems. It was shown that PAPP A levels are elevated in patients with unstable angina or acute myocardial infarction. Furthermore, PAPPA is believed to be involved in local proliferative processes such as wound healing ａnd bone remodeling. Moreover, PAPP-A is produced in high concentrations during pregnancy ａnd is released into the maternal circulation. In placenta, PAPP A is expressed in X cells in septa ａnd anchoring villi, ａnd in syncytiotrophoblasts in the chorionic villi.
Lower levels of PAPPA are found in an array of other tissues including kidney, myometrium, endometrium, ovaries, breast, prostate, bone marrow, colon, fibroblasts ａnd osteoblasts. PAPP-A is present in serum ａnd placenta during pregnancy; with levels increasing throughout pregnancy. Low levels of PAPP A are associated with a number of foetal chromosomal abnormalities, as well as pre-eclampsia ａnd stillbirth.
PAPPA levels may be a potentially highly specific marker for heart disease.
PAPP-A proteolytic activity is inhibited by targeting substrate exosite binding. Description PAPP-A Human Recombinant produced in E.Coli is single, a non-glycosylated, Polypeptide chain containing 191 amino acids fragment （81-271） corresponding to the PAPP-A "Jelly-Roll" domain fragment, having a total molecular mass of 30kDa ａnd fused with a 4.5kDa amino-terminal hexahistidine tag.
The PAPP-A is purified by proprietary chromatographic techniques. Source Escherichia Coli. Physical Appearance Sterile Filtered clear solution. Formulation PAPP-A protein is supplied in 1x PBS ａnd 50% glycerol. Stability Store at 4°C if entire vial will be used within 2-4 weeks.
Store, frozen at -20°C for longer periods of time.
Please avoid freeze thaw cycles. Purity Greater than 95.0% as determined by SDS-PAGE. Usage Prospec＇s products are furnished for LABORATORY RESEARCH USE ONLY. The product may not be used as drugs, agricultural or pesticidal products, food additives or household chemicals.
PAPP A Human/ 重组人妊娠联系质粒蛋白1
产品编号：ENZ-441
产品规格：2μg/10μg/1mg
Synonyms Pappalysin-1, Pregnancy-associated plasma protein A, PAPP-A, Insulin-like growth factor-dependent IGF-binding protein 4 protease, IGF-dependent IGFBP-4 protease, IGFBP-4ase, PAPPA, PAPA, DIPLA1, PAPPA1, ASBABP2. Introduction PAPPA is a large zinc binding protein, which acts as a metalloprotease ａnd specifically cleaves IGFBP-4 ａnd IGFBP-5, resulting in release of bound IGF. PAPP-A can also act as a regulator of IGF bioactivity in a number of biological systems, including the human ovary ａnd cardiovascular systems. It was shown that PAPP A levels are elevated in patients with unstable angina or acute myocardial infarction. Furthermore, PAPPA is believed to be involved in local proliferative processes such as wound healing ａnd bone remodeling. Moreover, PAPP-A is produced in high concentrations during pregnancy ａnd is released into the maternal circulation. In placenta, PAPP A is expressed in X cells in septa ａnd anchoring villi, ａnd in syncytiotrophoblasts in the chorionic villi.
Lower levels of PAPPA are found in an array of other tissues including kidney, myometrium, endometrium, ovaries, breast, prostate, bone marrow, colon, fibroblasts ａnd osteoblasts. PAPP-A is present in serum ａnd placenta during pregnancy; with levels increasing throughout pregnancy. Low levels of PAPP A are associated with a number of foetal chromosomal abnormalities, as well as pre-eclampsia ａnd stillbirth.
PAPPA levels may be a potentially highly specific marker for heart disease.
PAPP-A proteolytic activity is inhibited by targeting substrate exosite binding. Description PAPP-A Human Recombinant produced in E.Coli is single, a non-glycosylated, Polypeptide chain containing 191 amino acids fragment （81-271） corresponding to the PAPP-A "Jelly-Roll" domain fragment, having a total molecular mass of 30kDa ａnd fused with a 4.5kDa amino-terminal hexahistidine tag.
The PAPP-A is purified by proprietary chromatographic techniques. Source Escherichia Coli. Physical Appearance Sterile Filtered clear solution. Formulation PAPP-A protein is supplied in 1x PBS ａnd 50% glycerol. Stability Store at 4°C if entire vial will be used within 2-4 weeks.
Store, frozen at -20°C for longer periods of time.
Please avoid freeze thaw cycles. Purity Greater than 95.0% as determined by SDS-PAGE. Usage Prospec＇s products are furnished for LABORATORY RESEARCH USE ONLY. The product may not be used as drugs, agricultural or pesticidal products, food additives or household chemicals.
PAPP A Human/ 重组人妊娠联系质粒蛋白1
产品编号：ENZ-441
产品规格：2μg/10μg/1mg
Synonyms Pappalysin-1, Pregnancy-associated plasma protein A, PAPP-A, Insulin-like growth factor-dependent IGF-binding protein 4 protease, IGF-dependent IGFBP-4 protease, IGFBP-4ase, PAPPA, PAPA, DIPLA1, PAPPA1, ASBABP2. Introduction PAPPA is a large zinc binding protein, which acts as a metalloprotease ａnd specifically cleaves IGFBP-4 ａnd IGFBP-5, resulting in release of bound IGF. PAPP-A can also act as a regulator of IGF bioactivity in a number of biological systems, including the human ovary ａnd cardiovascular systems. It was shown that PAPP A levels are elevated in patients with unstable angina or acute myocardial infarction. Furthermore, PAPPA is believed to be involved in local proliferative processes such as wound healing ａnd bone remodeling. Moreover, PAPP-A is produced in high concentrations during pregnancy ａnd is released into the maternal circulation. In placenta, PAPP A is expressed in X cells in septa ａnd anchoring villi, ａnd in syncytiotrophoblasts in the chorionic villi.
Lower levels of PAPPA are found in an array of other tissues including kidney, myometrium, endometrium, ovaries, breast, prostate, bone marrow, colon, fibroblasts ａnd osteoblasts. PAPP-A is present in serum ａnd placenta during pregnancy; with levels increasing throughout pregnancy. Low levels of PAPP A are associated with a number of foetal chromosomal abnormalities, as well as pre-eclampsia ａnd stillbirth.
PAPPA levels may be a potentially highly specific marker for heart disease.
PAPP-A proteolytic activity is inhibited by targeting substrate exosite binding. Description PAPP-A Human Recombinant produced in E.Coli is single, a non-glycosylated, Polypeptide chain containing 191 amino acids fragment （81-271） corresponding to the PAPP-A "Jelly-Roll" domain fragment, having a total molecular mass of 30kDa ａnd fused with a 4.5kDa amino-terminal hexahistidine tag.
The PAPP-A is purified by proprietary chromatographic techniques. Source Escherichia Coli. Physical Appearance Sterile Filtered clear solution. Formulation PAPP-A protein is supplied in 1x PBS ａnd 50% glycerol. Stability Store at 4°C if entire vial will be used within 2-4 weeks.
Store, frozen at -20°C for longer periods of time.
Please avoid freeze thaw cycles. Purity Greater than 95.0% as determined by SDS-PAGE. Usage Prospec＇s products are furnished for LABORATORY RESEARCH USE ONLY. The product may not be used as drugs, agricultural or pesticidal products, food additives or household chemicals.
PAPP A Human/ 重组人妊娠联系质粒蛋白1
产品编号：ENZ-441
产品规格：2μg/10μg/1mg
Synonyms Pappalysin-1, Pregnancy-associated plasma protein A, PAPP-A, Insulin-like growth factor-dependent IGF-binding protein 4 protease, IGF-dependent IGFBP-4 protease, IGFBP-4ase, PAPPA, PAPA, DIPLA1, PAPPA1, ASBABP2. Introduction PAPPA is a large zinc binding protein, which acts as a metalloprotease ａnd specifically cleaves IGFBP-4 ａnd IGFBP-5, resulting in release of bound IGF. PAPP-A can also act as a regulator of IGF bioactivity in a number of biological systems, including the human ovary ａnd cardiovascular systems. It was shown that PAPP A levels are elevated in patients with unstable angina or acute myocardial infarction. Furthermore, PAPPA is believed to be involved in local proliferative processes such as wound healing ａnd bone remodeling. Moreover, PAPP-A is produced in high concentrations during pregnancy ａnd is released into the maternal circulation. In placenta, PAPP A is expressed in X cells in septa ａnd anchoring villi, ａnd in syncytiotrophoblasts in the chorionic villi.
Lower levels of PAPPA are found in an array of other tissues including kidney, myometrium, endometrium, ovaries, breast, prostate, bone marrow, colon, fibroblasts ａnd osteoblasts. PAPP-A is present in serum ａnd placenta during pregnancy; with levels increasing throughout pregnancy. Low levels of PAPP A are associated with a number of foetal chromosomal abnormalities, as well as pre-eclampsia ａnd stillbirth.
PAPPA levels may be a potentially highly specific marker for heart disease.
PAPP-A proteolytic activity is inhibited by targeting substrate exosite binding. Description PAPP-A Human Recombinant produced in E.Coli is single, a non-glycosylated, Polypeptide chain containing 191 amino acids fragment （81-271） corresponding to the PAPP-A "Jelly-Roll" domain fragment, having a total molecular mass of 30kDa ａnd fused with a 4.5kDa amino-terminal hexahistidine tag.
The PAPP-A is purified by proprietary chromatographic techniques. Source Escherichia Coli. Physical Appearance Sterile Filtered clear solution. Formulation PAPP-A protein is supplied in 1x PBS ａnd 50% glycerol. Stability Store at 4°C if entire vial will be used within 2-4 weeks.
Store, frozen at -20°C for longer periods of time.
Please avoid freeze thaw cycles. Purity Greater than 95.0% as determined by SDS-PAGE. Usage Prospec＇s products are furnished for LABORATORY RESEARCH USE ONLY. The product may not be used as drugs, agricultural or pesticidal products, food additives or household chemicals.
PAPP A Human/ 重组人妊娠联系质粒蛋白1
产品编号：ENZ-441
产品规格：2μg/10μg/1mg
Synonyms Pappalysin-1, Pregnancy-associated plasma protein A, PAPP-A, Insulin-like growth factor-dependent IGF-binding protein 4 protease, IGF-dependent IGFBP-4 protease, IGFBP-4ase, PAPPA, PAPA, DIPLA1, PAPPA1, ASBABP2. Introduction PAPPA is a large zinc binding protein, which acts as a metalloprotease ａnd specifically cleaves IGFBP-4 ａnd IGFBP-5, resulting in release of bound IGF. PAPP-A can also act as a regulator of IGF bioactivity in a number of biological systems, including the human ovary ａnd cardiovascular systems. It was shown that PAPP A levels are elevated in patients with unstable angina or acute myocardial infarction. Furthermore, PAPPA is believed to be involved in local proliferative processes such as wound healing ａnd bone remodeling. Moreover, PAPP-A is produced in high concentrations during pregnancy ａnd is released into the maternal circulation. In placenta, PAPP A is expressed in X cells in septa ａnd anchoring villi, ａnd in syncytiotrophoblasts in the chorionic villi.
Lower levels of PAPPA are found in an array of other tissues including kidney, myometrium, endometrium, ovaries, breast, prostate, bone marrow, colon, fibroblasts ａnd osteoblasts. PAPP-A is present in serum ａnd placenta during pregnancy; with levels increasing throughout pregnancy. Low levels of PAPP A are associated with a number of foetal chromosomal abnormalities, as well as pre-eclampsia ａnd stillbirth.
PAPPA levels may be a potentially highly specific marker for heart disease.
PAPP-A proteolytic activity is inhibited by targeting substrate exosite binding. Description PAPP-A Human Recombinant produced in E.Coli is single, a non-glycosylated, Polypeptide chain containing 191 amino acids fragment （81-271） corresponding to the PAPP-A "Jelly-Roll" domain fragment, having a total molecular mass of 30kDa ａnd fused with a 4.5kDa amino-terminal hexahistidine tag.
The PAPP-A is purified by proprietary chromatographic techniques. Source Escherichia Coli. Physical Appearance Sterile Filtered clear solution. Formulation PAPP-A protein is supplied in 1x PBS ａnd 50% glycerol. Stability Store at 4°C if entire vial will be used within 2-4 weeks.
Store, frozen at -20°C for longer periods of time.
Please avoid freeze thaw cycles. Purity Greater than 95.0% as determined by SDS-PAGE. Usage Prospec＇s products are furnished for LABORATORY RESEARCH USE ONLY. The product may not be used as drugs, agricultural or pesticidal products, food additives or household chemicals.
PAPP A Human/ 重组人妊娠联系质粒蛋白1
产品编号：ENZ-441
产品规格：2μg/10μg/1mg
Synonyms Pappalysin-1, Pregnancy-associated plasma protein A, PAPP-A, Insulin-like growth factor-dependent IGF-binding protein 4 protease, IGF-dependent IGFBP-4 protease, IGFBP-4ase, PAPPA, PAPA, DIPLA1, PAPPA1, ASBABP2. Introduction PAPPA is a large zinc binding protein, which acts as a metalloprotease ａnd specifically cleaves IGFBP-4 ａnd IGFBP-5, resulting in release of bound IGF. PAPP-A can also act as a regulator of IGF bioactivity in a number of biological systems, including the human ovary ａnd cardiovascular systems. It was shown that PAPP A levels are elevated in patients with unstable angina or acute myocardial infarction. Furthermore, PAPPA is believed to be involved in local proliferative processes such as wound healing ａnd bone remodeling. Moreover, PAPP-A is produced in high concentrations during pregnancy ａnd is released into the maternal circulation. In placenta, PAPP A is expressed in X cells in septa ａnd anchoring villi, ａnd in syncytiotrophoblasts in the chorionic villi.
Lower levels of PAPPA are found in an array of other tissues including kidney, myometrium, endometrium, ovaries, breast, prostate, bone marrow, colon, fibroblasts ａnd osteoblasts. PAPP-A is present in serum ａnd placenta during pregnancy; with levels increasing throughout pregnancy. Low levels of PAPP A are associated with a number of foetal chromosomal abnormalities, as well as pre-eclampsia ａnd stillbirth.
PAPPA levels may be a potentially highly specific marker for heart disease.
PAPP-A proteolytic activity is inhibited by targeting substrate exosite binding. Description PAPP-A Human Recombinant produced in E.Coli is single, a non-glycosylated, Polypeptide chain containing 191 amino acids fragment （81-271） corresponding to the PAPP-A "Jelly-Roll" domain fragment, having a total molecular mass of 30kDa ａnd fused with a 4.5kDa amino-terminal hexahistidine tag.
The PAPP-A is purified by proprietary chromatographic techniques. Source Escherichia Coli. Physical Appearance Sterile Filtered clear solution. Formulation PAPP-A protein is supplied in 1x PBS ａnd 50% glycerol. Stability Store at 4°C if entire vial will be used within 2-4 weeks.
Store, frozen at -20°C for longer periods of time.
Please avoid freeze thaw cycles. Purity Greater than 95.0% as determined by SDS-PAGE. Usage Prospec＇s products are furnished for LABORATORY RESEARCH USE ONLY. The product may not be used as drugs, agricultural or pesticidal products, food additives or household chemicals.
PAPP A Human/ 重组人妊娠联系质粒蛋白1
产品编号：ENZ-441
产品规格：2μg/10μg/1mg
Synonyms Pappalysin-1, Pregnancy-associated plasma protein A, PAPP-A, Insulin-like growth factor-dependent IGF-binding protein 4 protease, IGF-dependent IGFBP-4 protease, IGFBP-4ase, PAPPA, PAPA, DIPLA1, PAPPA1, ASBABP2. Introduction PAPPA is a large zinc binding protein, which acts as a metalloprotease ａnd specifically cleaves IGFBP-4 ａnd IGFBP-5, resulting in release of bound IGF. PAPP-A can also act as a regulator of IGF bioactivity in a number of biological systems, including the human ovary ａnd cardiovascular systems. It was shown that PAPP A levels are elevated in patients with unstable angina or acute myocardial infarction. Furthermore, PAPPA is believed to be involved in local proliferative processes such as wound healing ａnd bone remodeling. Moreover, PAPP-A is produced in high concentrations during pregnancy ａnd is released into the maternal circulation. In placenta, PAPP A is expressed in X cells in septa ａnd anchoring villi, ａnd in syncytiotrophoblasts in the chorionic villi.
Lower levels of PAPPA are found in an array of other tissues including kidney, myometrium, endometrium, ovaries, breast, prostate, bone marrow, colon, fibroblasts ａnd osteoblasts. PAPP-A is present in serum ａnd placenta during pregnancy; with levels increasing throughout pregnancy. Low levels of PAPP A are associated with a number of foetal chromosomal abnormalities, as well as pre-eclampsia ａnd stillbirth.
PAPPA levels may be a potentially highly specific marker for heart disease.
PAPP-A proteolytic activity is inhibited by targeting substrate exosite binding. Description PAPP-A Human Recombinant produced in E.Coli is single, a non-glycosylated, Polypeptide chain containing 191 amino acids fragment （81-271） corresponding to the PAPP-A "Jelly-Roll" domain fragment, having a total molecular mass of 30kDa ａnd fused with a 4.5kDa amino-terminal hexahistidine tag.
The PAPP-A is purified by proprietary chromatographic techniques. Source Escherichia Coli. Physical Appearance Sterile Filtered clear solution. Formulation PAPP-A protein is supplied in 1x PBS ａnd 50% glycerol. Stability Store at 4°C if entire vial will be used within 2-4 weeks.
Store, frozen at -20°C for longer periods of time.
Please avoid freeze thaw cycles. Purity Greater than 95.0% as determined by SDS-PAGE. Usage Prospec＇s products are furnished for LABORATORY RESEARCH USE ONLY. The product may not be used as drugs, agricultural or pesticidal products, food additives or household chemicals.
PAPP A Human/ 重组人妊娠联系质粒蛋白1
产品编号：ENZ-441
产品规格：2μg/10μg/1mg
Synonyms Pappalysin-1, Pregnancy-associated plasma protein A, PAPP-A, Insulin-like growth factor-dependent IGF-binding protein 4 protease, IGF-dependent IGFBP-4 protease, IGFBP-4ase, PAPPA, PAPA, DIPLA1, PAPPA1, ASBABP2. Introduction PAPPA is a large zinc binding protein, which acts as a metalloprotease ａnd specifically cleaves IGFBP-4 ａnd IGFBP-5, resulting in release of bound IGF. PAPP-A can also act as a regulator of IGF bioactivity in a number of biological systems, including the human ovary ａnd cardiovascular systems. It was shown that PAPP A levels are elevated in patients with unstable angina or acute myocardial infarction. Furthermore, PAPPA is believed to be involved in local proliferative processes such as wound healing ａnd bone remodeling. Moreover, PAPP-A is produced in high concentrations during pregnancy ａnd is released into the maternal circulation. In placenta, PAPP A is expressed in X cells in septa ａnd anchoring villi, ａnd in syncytiotrophoblasts in the chorionic villi.
Lower levels of PAPPA are found in an array of other tissues including kidney, myometrium, endometrium, ovaries, breast, prostate, bone marrow, colon, fibroblasts ａnd osteoblasts. PAPP-A is present in serum ａnd placenta during pregnancy; with levels increasing throughout pregnancy. Low levels of PAPP A are associated with a number of foetal chromosomal abnormalities, as well as pre-eclampsia ａnd stillbirth.
PAPPA levels may be a potentially highly specific marker for heart disease.
PAPP-A proteolytic activity is inhibited by targeting substrate exosite binding. Description PAPP-A Human Recombinant produced in E.Coli is single, a non-glycosylated, Polypeptide chain containing 191 amino acids fragment （81-271） corresponding to the PAPP-A "Jelly-Roll" domain fragment, having a total molecular mass of 30kDa ａnd fused with a 4.5kDa amino-terminal hexahistidine tag.
The PAPP-A is purified by proprietary chromatographic techniques. Source Escherichia Coli. Physical Appearance Sterile Filtered clear solution. Formulation PAPP-A protein is supplied in 1x PBS ａnd 50% glycerol. Stability Store at 4°C if entire vial will be used within 2-4 weeks.
Store, frozen at -20°C for longer periods of time.
Please avoid freeze thaw cycles. Purity Greater than 95.0% as determined by SDS-PAGE. Usage Prospec＇s products are furnished for LABORATORY RESEARCH USE ONLY. The product may not be used as drugs, agricultural or pesticidal products, food additives or household chemicals.
PAPP A Human/ 重组人妊娠联系质粒蛋白1
产品编号：ENZ-441
产品规格：2μg/10μg/1mg
Synonyms Pappalysin-1, Pregnancy-associated plasma protein A, PAPP-A, Insulin-like growth factor-dependent IGF-binding protein 4 protease, IGF-dependent IGFBP-4 protease, IGFBP-4ase, PAPPA, PAPA, DIPLA1, PAPPA1, ASBABP2. Introduction PAPPA is a large zinc binding protein, which acts as a metalloprotease ａnd specifically cleaves IGFBP-4 ａnd IGFBP-5, resulting in release of bound IGF. PAPP-A can also act as a regulator of IGF bioactivity in a number of biological systems, including the human ovary ａnd cardiovascular systems. It was shown that PAPP A levels are elevated in patients with unstable angina or acute myocardial infarction. Furthermore, PAPPA is believed to be involved in local proliferative processes such as wound healing ａnd bone remodeling. Moreover, PAPP-A is produced in high concentrations during pregnancy ａnd is released into the maternal circulation. In placenta, PAPP A is expressed in X cells in septa ａnd anchoring villi, ａnd in syncytiotrophoblasts in the chorionic villi.
Lower levels of PAPPA are found in an array of other tissues including kidney, myometrium, endometrium, ovaries, breast, prostate, bone marrow, colon, fibroblasts ａnd osteoblasts. PAPP-A is present in serum ａnd placenta during pregnancy; with levels increasing throughout pregnancy. Low levels of PAPP A are associated with a number of foetal chromosomal abnormalities, as well as pre-eclampsia ａnd stillbirth.
PAPPA levels may be a potentially highly specific marker for heart disease.
PAPP-A proteolytic activity is inhibited by targeting substrate exosite binding. Description PAPP-A Human Recombinant produced in E.Coli is single, a non-glycosylated, Polypeptide chain containing 191 amino acids fragment （81-271） corresponding to the PAPP-A "Jelly-Roll" domain fragment, having a total molecular mass of 30kDa ａnd fused with a 4.5kDa amino-terminal hexahistidine tag.
The PAPP-A is purified by proprietary chromatographic techniques. Source Escherichia Coli. Physical Appearance Sterile Filtered clear solution. Formulation PAPP-A protein is supplied in 1x PBS ａnd 50% glycerol. Stability Store at 4°C if entire vial will be used within 2-4 weeks.
Store, frozen at -20°C for longer periods of time.
Please avoid freeze thaw cycles. Purity Greater than 95.0% as determined by SDS-PAGE. Usage Prospec＇s products are furnished for LABORATORY RESEARCH USE ONLY. The product may not be used as drugs, agricultural or pesticidal products, food additives or household chemicals.
PAPP A Human/ 重组人妊娠联系质粒蛋白1
产品编号：ENZ-441
产品规格：2μg/10μg/1mg
Synonyms Pappalysin-1, Pregnancy-associated plasma protein A, PAPP-A, Insulin-like growth factor-dependent IGF-binding protein 4 protease, IGF-dependent IGFBP-4 protease, IGFBP-4ase, PAPPA, PAPA, DIPLA1, PAPPA1, ASBABP2. Introduction PAPPA is a large zinc binding protein, which acts as a metalloprotease ａnd specifically cleaves IGFBP-4 ａnd IGFBP-5, resulting in release of bound IGF. PAPP-A can also act as a regulator of IGF bioactivity in a number of biological systems, including the human ovary ａnd cardiovascular systems. It was shown that PAPP A levels are elevated in patients with unstable angina or acute myocardial infarction. Furthermore, PAPPA is believed to be involved in local proliferative processes such as wound healing ａnd bone remodeling. Moreover, PAPP-A is produced in high concentrations during pregnancy ａnd is released into the maternal circulation. In placenta, PAPP A is expressed in X cells in septa ａnd anchoring villi, ａnd in syncytiotrophoblasts in the chorionic villi.
Lower levels of PAPPA are found in an array of other tissues including kidney, myometrium, endometrium, ovaries, breast, prostate, bone marrow, colon, fibroblasts ａnd osteoblasts. PAPP-A is present in serum ａnd placenta during pregnancy; with levels increasing throughout pregnancy. Low levels of PAPP A are associated with a number of foetal chromosomal abnormalities, as well as pre-eclampsia ａnd stillbirth.
PAPPA levels may be a potentially highly specific marker for heart disease.
PAPP-A proteolytic activity is inhibited by targeting substrate exosite binding. Description PAPP-A Human Recombinant produced in E.Coli is single, a non-glycosylated, Polypeptide chain containing 191 amino acids fragment （81-271） corresponding to the PAPP-A "Jelly-Roll" domain fragment, having a total molecular mass of 30kDa ａnd fused with a 4.5kDa amino-terminal hexahistidine tag.
The PAPP-A is purified by proprietary chromatographic techniques. Source Escherichia Coli. Physical Appearance Sterile Filtered clear solution. Formulation PAPP-A protein is supplied in 1x PBS ａnd 50% glycerol. Stability Store at 4°C if entire vial will be used within 2-4 weeks.
Store, frozen at -20°C for longer periods of time.
Please avoid freeze thaw cycles. Purity Greater than 95.0% as determined by SDS-PAGE. Usage Prospec＇s products are furnished for LABORATORY RESEARCH USE ONLY. The product may not be used as drugs, agricultural or pesticidal products, food additives or household chemicals.
PAPP A Human/ 重组人妊娠联系质粒蛋白1
产品编号：ENZ-441
产品规格：2μg/10μg/1mg
Synonyms Pappalysin-1, Pregnancy-associated plasma protein A, PAPP-A, Insulin-like growth factor-dependent IGF-binding protein 4 protease, IGF-dependent IGFBP-4 protease, IGFBP-4ase, PAPPA, PAPA, DIPLA1, PAPPA1, ASBABP2. Introduction PAPPA is a large zinc binding protein, which acts as a metalloprotease ａnd specifically cleaves IGFBP-4 ａnd IGFBP-5, resulting in release of bound IGF. PAPP-A can also act as a regulator of IGF bioactivity in a number of biological systems, including the human ovary ａnd cardiovascular systems. It was shown that PAPP A levels are elevated in patients with unstable angina or acute myocardial infarction. Furthermore, PAPPA is believed to be involved in local proliferative processes such as wound healing ａnd bone remodeling. Moreover, PAPP-A is produced in high concentrations during pregnancy ａnd is released into the maternal circulation. In placenta, PAPP A is expressed in X cells in septa ａnd anchoring villi, ａnd in syncytiotrophoblasts in the chorionic villi.
Lower levels of PAPPA are found in an array of other tissues including kidney, myometrium, endometrium, ovaries, breast, prostate, bone marrow, colon, fibroblasts ａnd osteoblasts. PAPP-A is present in serum ａnd placenta during pregnancy; with levels increasing throughout pregnancy. Low levels of PAPP A are associated with a number of foetal chromosomal abnormalities, as well as pre-eclampsia ａnd stillbirth.
PAPPA levels may be a potentially highly specific marker for heart disease.
PAPP-A proteolytic activity is inhibited by targeting substrate exosite binding. Description PAPP-A Human Recombinant produced in E.Coli is single, a non-glycosylated, Polypeptide chain containing 191 amino acids fragment （81-271） corresponding to the PAPP-A "Jelly-Roll" domain fragment, having a total molecular mass of 30kDa ａnd fused with a 4.5kDa amino-terminal hexahistidine tag.
The PAPP-A is purified by proprietary chromatographic techniques. Source Escherichia Coli. Physical Appearance Sterile Filtered clear solution. Formulation PAPP-A protein is supplied in 1x PBS ａnd 50% glycerol. Stability Store at 4°C if entire vial will be used within 2-4 weeks.
Store, frozen at -20°C for longer periods of time.
Please avoid freeze thaw cycles. Purity Greater than 95.0% as determined by SDS-PAGE. Usage Prospec＇s products are furnished for LABORATORY RESEARCH USE ONLY. The product may not be used as drugs, agricultural or pesticidal products, food additives or household chemicals.
PAPP A Human/ 重组人妊娠联系质粒蛋白1
产品编号：ENZ-441
产品规格：2μg/10μg/1mg
Synonyms Pappalysin-1, Pregnancy-associated plasma protein A, PAPP-A, Insulin-like growth factor-dependent IGF-binding protein 4 protease, IGF-dependent IGFBP-4 protease, IGFBP-4ase, PAPPA, PAPA, DIPLA1, PAPPA1, ASBABP2. Introduction PAPPA is a large zinc binding protein, which acts as a metalloprotease ａnd specifically cleaves IGFBP-4 ａnd IGFBP-5, resulting in release of bound IGF. PAPP-A can also act as a regulator of IGF bioactivity in a number of biological systems, including the human ovary ａnd cardiovascular systems. It was shown that PAPP A levels are elevated in patients with unstable angina or acute myocardial infarction. Furthermore, PAPPA is believed to be involved in local proliferative processes such as wound healing ａnd bone remodeling. Moreover, PAPP-A is produced in high concentrations during pregnancy ａnd is released into the maternal circulation. In placenta, PAPP A is expressed in X cells in septa ａnd anchoring villi, ａnd in syncytiotrophoblasts in the chorionic villi.
Lower levels of PAPPA are found in an array of other tissues including kidney, myometrium, endometrium, ovaries, breast, prostate, bone marrow, colon, fibroblasts ａnd osteoblasts. PAPP-A is present in serum ａnd placenta during pregnancy; with levels increasing throughout pregnancy. Low levels of PAPP A are associated with a number of foetal chromosomal abnormalities, as well as pre-eclampsia ａnd stillbirth.
PAPPA levels may be a potentially highly specific marker for heart disease.
PAPP-A proteolytic activity is inhibited by targeting substrate exosite binding. Description PAPP-A Human Recombinant produced in E.Coli is single, a non-glycosylated, Polypeptide chain containing 191 amino acids fragment （81-271） corresponding to the PAPP-A "Jelly-Roll" domain fragment, having a total molecular mass of 30kDa ａnd fused with a 4.5kDa amino-terminal hexahistidine tag.
The PAPP-A is purified by proprietary chromatographic techniques. Source Escherichia Coli. Physical Appearance Sterile Filtered clear solution. Formulation PAPP-A protein is supplied in 1x PBS ａnd 50% glycerol. Stability Store at 4°C if entire vial will be used within 2-4 weeks.
Store, frozen at -20°C for longer periods of time.
Please avoid freeze thaw cycles. Purity Greater than 95.0% as determined by SDS-PAGE. Usage Prospec＇s products are furnished for LABORATORY RESEARCH USE ONLY. The product may not be used as drugs, agricultural or pesticidal products, food additives or household chemicals.
PAPP A Human/ 重组人妊娠联系质粒蛋白1
产品编号：ENZ-441
产品规格：2μg/10μg/1mg
产品规格：2μg/10μg/1mg
| Synonyms | Pappalysin-1, Pregnancy-associated plasma protein A, PAPP-A, Insulin-like growth factor-dependent IGF-binding protein 4 protease, IGF-dependent IGFBP-4 protease, IGFBP-4ase, PAPPA, PAPA, DIPLA1, PAPPA1, ASBABP2. |
| Introduction | PAPPA is a large zinc binding protein, which acts as a metalloprotease ａnd specifically cleaves IGFBP-4 ａnd IGFBP-5, resulting in release of bound IGF. PAPP-A can also act as a regulator of IGF bioactivity in a number of biological systems, including the human ovary ａnd cardiovascular systems. It was shown that PAPP A levels are elevated in patients with unstable angina or acute myocardial infarction. Furthermore, PAPPA is believed to be involved in local proliferative processes such as wound healing ａnd bone remodeling. Moreover, PAPP-A is produced in high concentrations during pregnancy ａnd is released into the maternal circulation. In placenta, PAPP A is expressed in X cells in septa ａnd anchoring villi, ａnd in syncytiotrophoblasts in the chorionic villi. Lower levels of PAPPA are found in an array of other tissues including kidney, myometrium, endometrium, ovaries, breast, prostate, bone marrow, colon, fibroblasts ａnd osteoblasts. PAPP-A is present in serum ａnd placenta during pregnancy; with levels increasing throughout pregnancy. Low levels of PAPP A are associated with a number of foetal chromosomal abnormalities, as well as pre-eclampsia ａnd stillbirth. PAPPA levels may be a potentially highly specific marker for heart disease. PAPP-A proteolytic activity is inhibited by targeting substrate exosite binding. |
| Description | PAPP-A Human Recombinant produced in E.Coli is single, a non-glycosylated, Polypeptide chain containing 191 amino acids fragment （81-271） corresponding to the PAPP-A "Jelly-Roll" domain fragment, having a total molecular mass of 30kDa ａnd fused with a 4.5kDa amino-terminal hexahistidine tag. The PAPP-A is purified by proprietary chromatographic techniques. |
| Source | Escherichia Coli. |
| Physical Appearance | Sterile Filtered clear solution. |
| Formulation | PAPP-A protein is supplied in 1x PBS ａnd 50% glycerol. |
| Stability | Store at 4°C if entire vial will be used within 2-4 weeks. Store, frozen at -20°C for longer periods of time. Please avoid freeze thaw cycles. |
| Purity | Greater than 95.0% as determined by SDS-PAGE. |
| Usage | Prospec＇s products are furnished for LABORATORY RESEARCH USE ONLY. The product may not be used as drugs, agricultural or pesticidal products, food additives or household chemicals. |
